JP2011527301A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011527301A5 JP2011527301A5 JP2011517038A JP2011517038A JP2011527301A5 JP 2011527301 A5 JP2011527301 A5 JP 2011527301A5 JP 2011517038 A JP2011517038 A JP 2011517038A JP 2011517038 A JP2011517038 A JP 2011517038A JP 2011527301 A5 JP2011527301 A5 JP 2011527301A5
- Authority
- JP
- Japan
- Prior art keywords
- vwf
- fviii
- medicament according
- administered
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100019017 VWF Human genes 0.000 claims 23
- 108010047303 von Willebrand Factor Proteins 0.000 claims 23
- 229960001134 von Willebrand factor Drugs 0.000 claims 23
- 102100000368 F8 Human genes 0.000 claims 10
- 101700070229 F8 Proteins 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 210000001772 Blood Platelets Anatomy 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 206010018987 Haemorrhage Diseases 0.000 claims 3
- 206010035534 Platelet disease Diseases 0.000 claims 3
- 230000000740 bleeding Effects 0.000 claims 3
- 231100000319 bleeding Toxicity 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102100019727 P2RY1 Human genes 0.000 claims 2
- 101700062635 P2RY1 Proteins 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 2
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 claims 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 claims 1
- 229960003009 Clopidogrel Drugs 0.000 claims 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N Clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims 1
- 108010054218 Factor VIII Proteins 0.000 claims 1
- 102000001690 Factor VIII Human genes 0.000 claims 1
- 229960000301 Factor VIII Drugs 0.000 claims 1
- 229940003169 Factor VIII / von Willebrand factor Drugs 0.000 claims 1
- 210000002381 Plasma Anatomy 0.000 claims 1
- 102000007312 Recombinant Proteins Human genes 0.000 claims 1
- 108010033725 Recombinant Proteins Proteins 0.000 claims 1
- 229960005001 Ticlopidine Drugs 0.000 claims 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N Ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 230000002605 anti-dotal Effects 0.000 claims 1
- 239000000729 antidote Substances 0.000 claims 1
- 239000012141 concentrate Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Claims (12)
- 血小板を阻害する物質により誘発される血小板障害と関連する出血性イベントを治療および／または予防するための、薬学的有効量のフォン・ヴィレブランド因子（ｖＷＦ）を含む医薬。
- ｖＷＦが第ＶＩＩＩ因子／フォン・ヴィレブランド因子（ＦＶＩＩＩ／ｖＷＦ）の組み合わせ物として第ＶＩＩＩ因子と組み合わせて使用または投与される、請求項１に記載の医薬。
- 解毒剤として作用させるために前記ｖＷＦまたはＦＶＩＩＩ／ｖＷＦを投与する、請求項１または２に記載の医薬。
- ｖＷＦまたはＦＶＩＩＩ／ｖＷＦが濃縮物として使用または投与される、請求項１〜３のいずれか１項に記載の医薬。
- ｖＷＦまたはＦＶＩＩＩ／ｖＷＦがヒト血漿から単離されている、請求項１〜４のいずれか１項に記載の医薬。
- ｖＷＦまたはＦＶＩＩＩ／ｖＷＦが組み換えタンパク質として投与される、請求項１〜５のいずれか１項に記載の医薬。
- ｖＷＦまたはＦＶＩＩＩ／ｖＷＦが体重１ｋｇあたり１０〜１０００単位ｖＷＦ、または体重１ｋｇあたり５〜４００単位ＦＶＩＩＩおよび１０〜１０００単位ｖＷＦの用量で患者に投与される、請求項１〜６のいずれか１項に記載の医薬。
- ｖＷＦまたはＦＶＩＩＩ／ｖＷＦが体重１ｋｇあたり３０〜５００単位ｖＷＦまたは体重１ｋｇあたり２０〜２００単位ＦＶＩＩＩおよび３０〜５００単位ｖＷＦの用量で患者に投与される、請求項７に記載の医薬。
- 血小板を阻害する物質がシクロオキシゲナーゼ（ｃｙｃｌｏｏｘｉｇｅｎａｓｅ）イン
ヒビター、ＡＤＰ受容体のインヒビターまたはそれらの組み合わせ物である、請求項１〜８のいずれか１項に記載の医薬。 - シクロオキシゲナーゼインヒビターがアセチルサリチル酸であり、そしてＡＤＰ受容体のインヒビターがチエノピリジノ誘導体、好ましくはクロピドグレルまたはチクロピジンである、請求項９に記載の医薬。
- 血小板を阻害する物質により誘発される血小板障害と関連する出血性イベントの治療および／または予防に使用するための、同時の、別々の、または逐次的な使用のためのｖＷＦおよびＦＶＩＩＩを組合わせた医薬組成物。
- 血小板を阻害する物質により誘発される血小板障害と関連する出血性イベントに関係する障害を治療および／または予防するための医薬を製造するための、薬学的有効量のフォン・ヴィレブランド因子（ｖＷＦ）の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102008032361A DE102008032361A1 (de) | 2008-07-10 | 2008-07-10 | Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie |
| DE102008032361.6 | 2008-07-10 | ||
| PCT/EP2009/005027 WO2010003687A1 (en) | 2008-07-10 | 2009-07-10 | Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011527301A JP2011527301A (ja) | 2011-10-27 |
| JP2011527301A5 true JP2011527301A5 (ja) | 2012-07-26 |
| JP5653916B2 JP5653916B2 (ja) | 2015-01-14 |
Family
ID=41171229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517038A Active JP5653916B2 (ja) | 2008-07-10 | 2009-07-10 | 血小板のインヒビターにより誘発される凝固障害を治療するためのフォン・ヴィレブランド因子または第ｖｉｉｉ因子およびフォン・ヴィレブランド因子 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US8603979B2 (ja) |
| EP (1) | EP2310043B2 (ja) |
| JP (1) | JP5653916B2 (ja) |
| KR (1) | KR20110043654A (ja) |
| CN (1) | CN102088999A (ja) |
| AU (1) | AU2009268289B2 (ja) |
| CA (1) | CA2730290C (ja) |
| DE (1) | DE102008032361A1 (ja) |
| DK (1) | DK2310043T4 (ja) |
| ES (1) | ES2395855T5 (ja) |
| PL (1) | PL2310043T5 (ja) |
| RU (1) | RU2563236C2 (ja) |
| WO (1) | WO2010003687A1 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
| EP3936116A1 (en) | 2007-12-28 | 2022-01-12 | Takeda Pharmaceutical Company Limited | Rrecombinant vwf containing formulations |
| CN102066417B (zh) * | 2008-06-24 | 2015-11-25 | 奥克塔法马股份有限公司 | 提纯凝固因子viii的方法 |
| DE102008032361A1 (de) * | 2008-07-10 | 2010-01-21 | Csl Behring Gmbh | Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie |
| PT2349314E (pt) * | 2008-10-21 | 2013-05-28 | Baxter Int | Formulações de vwf recombinante liofilizado |
| LT2804623T (lt) | 2012-01-12 | 2019-12-10 | Bioverativ Therapeutics Inc | Chimeriniai viii faktoriaus polipeptidai ir jų panaudojimas |
| US20150080309A1 (en) | 2012-04-24 | 2015-03-19 | Nova Nordisk A/S | Compounds Suitable for Treatment of Haemophilia |
| EP2662083A1 (en) | 2012-05-08 | 2013-11-13 | CSL Behring GmbH | Sugar compositions for treating hemophilia a and/or von willebrand disease |
| CN102776260B (zh) * | 2012-07-26 | 2015-04-29 | 上海泰龙生物医药科技有限公司 | 一种高效表达重组人凝血八因子的方法 |
| EP2796145B1 (en) | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| CN103263663B (zh) * | 2013-06-08 | 2016-05-04 | 兆科药业（合肥）有限公司 | 一种抗血小板溶栓素在制备治疗vwf缺陷型血管栓塞性疾病的药物中的应用 |
| WO2014210546A1 (en) | 2013-06-27 | 2014-12-31 | University Of Washington Through Its Center For Commercialization | Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4430205A1 (de) | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung |
| US6518482B2 (en) | 1994-09-13 | 2003-02-11 | American National Red Cross | Transgenic non-human mammals expressing human coagulation factor VIII and von Willebrand factor |
| DE4437544A1 (de) | 1994-10-20 | 1996-04-25 | Behringwerke Ag | Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika |
| FR2744918B1 (fr) * | 1996-02-19 | 1998-05-07 | Sanofi Sa | Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique |
| FI974321A0 (fi) * | 1997-11-25 | 1997-11-25 | Jenny Ja Antti Wihurin Rahasto | Multipel heparinglykosaminoglykan och en proteoglykan innehaollande dessa |
| US7033994B2 (en) † | 1999-12-24 | 2006-04-25 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy |
| DE102008032361A1 (de) * | 2008-07-10 | 2010-01-21 | Csl Behring Gmbh | Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie |
-
2008
- 2008-07-10 DE DE102008032361A patent/DE102008032361A1/de not_active Withdrawn
-
2009
- 2009-07-10 CN CN2009801264767A patent/CN102088999A/zh active Pending
- 2009-07-10 US US13/003,139 patent/US8603979B2/en active Active
- 2009-07-10 DK DK09777111.7T patent/DK2310043T4/da active
- 2009-07-10 KR KR1020117002934A patent/KR20110043654A/ko not_active Application Discontinuation
- 2009-07-10 RU RU2011104705/15A patent/RU2563236C2/ru active
- 2009-07-10 AU AU2009268289A patent/AU2009268289B2/en active Active
- 2009-07-10 PL PL09777111.7T patent/PL2310043T5/pl unknown
- 2009-07-10 WO PCT/EP2009/005027 patent/WO2010003687A1/en active Application Filing
- 2009-07-10 EP EP09777111.7A patent/EP2310043B2/en active Active
- 2009-07-10 ES ES09777111T patent/ES2395855T5/es active Active
- 2009-07-10 CA CA2730290A patent/CA2730290C/en active Active
- 2009-07-10 JP JP2011517038A patent/JP5653916B2/ja active Active
-
2013
- 2013-11-04 US US14/071,193 patent/US9095564B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011527301A5 (ja) | ||
| RU2011104705A (ru) | Фактор фон виллебранда или фактор viii и фактор фон виллебранда для лечения коагулопатии, индуцированной ингибиторами тромбоцитов | |
| Kolomaznik et al. | Pulmonary surfactant and bacterial lipopolysaccharide: the interaction and its functional consequences. | |
| HRP20171939T1 (hr) | Formulacija protutijela i režimi terapije | |
| HRP20191070T1 (hr) | Intervencije na bazi angiopoietina za liječenje cerebralne malarije | |
| BR112014016085A2 (pt) | composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico | |
| BR112017006957A2 (pt) | formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| HRP20150375T1 (hr) | Derivati piridazinona | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112015012197A2 (pt) | terapia de combinação | |
| JP2015517488A5 (ja) | ||
| JP2010132695A5 (ja) | ||
| JP2015512406A5 (ja) | ||
| JP2010525050A5 (ja) | ||
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| HRP20240082T1 (hr) | Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| CO5550426A2 (es) | Novedoso metodo terapeutico | |
| HRP20212030T1 (hr) | Kombinacija koja sadrži palbociklib i 6-(2,4-diklorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirolidin-3-il]oksifenil]-8,9-dihidro-7h-benzo[7]anulen-2-karboksilnu kiselinu i njezina upotreba u liječenju raka | |
| JP2009543885A5 (ja) | ||
| JP2015512927A5 (ja) | ||
| JP2016530291A5 (ja) | ||
| SI2413933T1 (en) | 2,4,6-TRIUFLORO-N- (6- (1-METHYL-PIPERIDIN-4-CARBONYL) -PYRIDIN-2-YL)-BENZAMIDE FOR THRESHOLD OF MIGRINE OVER ORAL OR INTRAVEN | |
| JP2020500864A5 (ja) |